Literature DB >> 22382681

Doxorubicin induces the persistent activation of intracellular transglutaminase 2 that protects from cell death.

Sung-Yup Cho1, Eui Man Jeong, Jin-Haeng Lee, Hyo-Jun Kim, Jisun Lim, Chai-Wan Kim, Dong-Myung Shin, Ju-Hong Jeon, Kyungho Choi, In-Gyu Kim.   

Abstract

The activation of transglutaminase 2 (TG2), an enzyme that catalyzes post-translational modifications of proteins, has been implicated in apoptosis, cell adhesion and inflammatory responses. We previously reported that intracellular TG2 is activated under oxidative stress conditions, such as ultraviolet irradiation, ischemia-reperfusion, and hypoxia. In this study, we examined the effect of genotoxic stress on the intracellular activity of TG2 using doxorubicin which generates reactive oxygen species that lead to double-strand breakage of DNA. We demonstrated that doxorubicin elicits the persistent activation of TG2. Doxorubicin-induced TG2 activity was suppressed by treatment with caffeine at the early phase, N-acetylcysteine at the mid-phase, and EGTA at the late phase. However, treatment with a blocking antibody against TGFβ or toll-like receptor 2 showed no effect on TG2 activity, indicating that at least three different signaling pathways may be involved in the process of TG2 activation. In addition, using MEF cells defective for TG2 and cells overexpressing an activesite mutant of TG2, we revealed that doxorubicin-induced cell death is inversely correlated with TG2 activity. Our findings indicate that the persistent activation of TG2 by doxorubicin contributes to cell survival, suggesting that the mechanism-based inhibition of TG2 may be a novel strategy to prevent drug-resistance in doxorubicin treatment.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22382681      PMCID: PMC3887707          DOI: 10.1007/s10059-012-2201-9

Source DB:  PubMed          Journal:  Mol Cells        ISSN: 1016-8478            Impact factor:   5.034


  36 in total

1.  Cystamine prevents ischemia-reperfusion injury by inhibiting polyamination of RhoA.

Authors:  Dong-Myung Shin; Jinmo Kang; Jongwon Ha; Heun-Soo Kang; Sang-Chul Park; In-Gyu Kim; Sang Joon Kim
Journal:  Biochem Biophys Res Commun       Date:  2007-11-20       Impact factor: 3.575

2.  Time and dose-dependent activation of p53 serine 15 phosphorylation among cell lines with different radiation sensitivity.

Authors:  Michael Wittlinger; Gerhard G Grabenbauer; Carl N Sprung; Rolf Sauer; Luitpold V R Distel
Journal:  Int J Radiat Biol       Date:  2007-04       Impact factor: 2.694

Review 3.  Ataxia-telangiectasia: from a rare disorder to a paradigm for cell signalling and cancer.

Authors:  Martin F Lavin
Journal:  Nat Rev Mol Cell Biol       Date:  2008-10       Impact factor: 94.444

4.  Transglutaminase 2 suppresses apoptosis by modulating caspase 3 and NF-kappaB activity in hypoxic tumor cells.

Authors:  G-Y Jang; J-H Jeon; S-Y Cho; D-M Shin; C-W Kim; E M Jeong; H C Bae; T W Kim; S-H Lee; Y Choi; D-S Lee; S-C Park; I-G Kim
Journal:  Oncogene       Date:  2009-10-19       Impact factor: 9.867

5.  Degradation of transglutaminase 2 by calcium-mediated ubiquitination responding to high oxidative stress.

Authors:  Eui Man Jeong; Chai-Wan Kim; Sung-Yup Cho; Gi-Yong Jang; Dong-Myung Shin; Ju-Hong Jeon; In-Gyu Kim
Journal:  FEBS Lett       Date:  2009-02-01       Impact factor: 4.124

Review 6.  Modulation of cellular response to anticancer treatment by caffeine: inhibition of cell cycle checkpoints, DNA repair and more.

Authors:  Michal Sabisz; Andrzej Skladanowski
Journal:  Curr Pharm Biotechnol       Date:  2008-08       Impact factor: 2.837

Review 7.  Transglutaminases and disease: lessons from genetically engineered mouse models and inherited disorders.

Authors:  Siiri E Iismaa; Bryony M Mearns; Laszlo Lorand; Robert M Graham
Journal:  Physiol Rev       Date:  2009-07       Impact factor: 37.312

8.  Epithelial transglutaminase 2 is needed for T cell interleukin-17 production and subsequent pulmonary inflammation and fibrosis in bleomycin-treated mice.

Authors:  Keunhee Oh; Hyung-Bae Park; Ok-Jin Byoun; Dong-Myung Shin; Eui Man Jeong; Young Whan Kim; Yon Su Kim; Gerry Melino; In-Gyu Kim; Dong-Sup Lee
Journal:  J Exp Med       Date:  2011-07-11       Impact factor: 14.307

9.  Silencing of TGase 2 sensitizes breast cancer cells to apoptosis by regulation of survival factors.

Authors:  Dae-Seok Kim; Kang-Seo Park; Soo-Youl Kim
Journal:  Front Biosci (Landmark Ed)       Date:  2009-01-01

10.  Increase in transglutaminase 2 expression is associated with NF-kappaB activation in breast cancer tissues.

Authors:  Kang-Seo Park; Dae-Seok Kim; Kyung-Chae Jeong; Soo-Youl Kim
Journal:  Front Biosci (Landmark Ed)       Date:  2009-01-01
View more
  11 in total

1.  Silencing of TGM2 reverses epithelial to mesenchymal transition and modulates the chemosensitivity of breast cancer to docetaxel.

Authors:  Wenxing He; Zhengkui Sun; Zhiming Liu
Journal:  Exp Ther Med       Date:  2015-08-12       Impact factor: 2.447

2.  TGM2: a cell surface marker in esophageal adenocarcinomas.

Authors:  Deborah T Leicht; Tasneem Kausar; Zhuwen Wang; Daysha Ferrer-Torres; Thomas D Wang; Dafydd G Thomas; Jules Lin; Andrew C Chang; Lin Lin; David G Beer
Journal:  J Thorac Oncol       Date:  2014-06       Impact factor: 15.609

3.  Intracellular construction of topology-controlled polypeptide nanostructures with diverse biological functions.

Authors:  Li-Li Li; Sheng-Lin Qiao; Wei-Jiao Liu; Yang Ma; Dong Wan; Jie Pan; Hao Wang
Journal:  Nat Commun       Date:  2017-11-02       Impact factor: 14.919

4.  Keratinocyte transglutaminase 2 promotes CCR6+ γδT-cell recruitment by upregulating CCL20 in psoriatic inflammation.

Authors:  Ji-Woong Shin; Mee-Ae Kwon; Jinha Hwang; Seok-Jin Lee; Jin-Haeng Lee; Hyo-Jun Kim; Ki Baek Lee; Soo-Jin Lee; Eui Man Jeong; Jin Ho Chung; In-Gyu Kim
Journal:  Cell Death Dis       Date:  2020-04-30       Impact factor: 8.469

5.  Transglutaminase 2 mediates hypoxia-induced selective mRNA translation via polyamination of 4EBPs.

Authors:  Sung-Yup Cho; Seungun Lee; Jeonghun Yeom; Hyo-Jun Kim; Jin-Haeng Lee; Ji-Woong Shin; Mee-Ae Kwon; Ki Baek Lee; Eui Man Jeong; Hee Sung Ahn; Dong-Myung Shin; Kyunggon Kim; In-Gyu Kim
Journal:  Life Sci Alliance       Date:  2020-02-19

6.  Transglutaminase 2 crosslinks the glutathione S-transferase tag, impeding protein-protein interactions of the fused protein.

Authors:  Hyo-Jun Kim; Jin-Haeng Lee; Ki Baek Lee; Ji-Woong Shin; Mee-Ae Kwon; Soojin Lee; Eui Man Jeong; Sung-Yup Cho; In-Gyu Kim
Journal:  Exp Mol Med       Date:  2021-01-13       Impact factor: 8.718

7.  The Motility and Mesenchymal Features of Breast Cancer Cells Correlate with the Levels and Intracellular Localization of Transglutaminase Type 2.

Authors:  Nicoletta Bianchi; Federica Brugnoli; Silvia Grassilli; Karine Bourgeois; Jeffrey W Keillor; Carlo M Bergamini; Gianluca Aguiari; Stefano Volinia; Valeria Bertagnolo
Journal:  Cells       Date:  2021-11-06       Impact factor: 6.600

8.  Double-Stranded RNA Enhances Matrix Metalloproteinase-1 and -13 Expressions through TLR3-Dependent Activation of Transglutaminase 2 in Dermal Fibroblasts.

Authors:  Ah-Young Hong; Seok-Jin Lee; Ki Baek Lee; Ji-Woong Shin; Eui Man Jeong; In-Gyu Kim
Journal:  Int J Mol Sci       Date:  2022-02-28       Impact factor: 5.923

9.  Transglutaminase-2 Is Involved in All-Trans Retinoic Acid-Induced Invasion and Matrix Metalloproteinases Expression of SH-SY5Y Neuroblastoma Cells via NF-κB Pathway.

Authors:  Hye Ja Lee; Mi Kyung Park; Hyun Cheol Bae; Hee Jung Yoon; Soo Youl Kim; Chang Hoon Lee
Journal:  Biomol Ther (Seoul)       Date:  2012-05       Impact factor: 4.634

10.  Amplification of transglutaminase 2 enhances tumor-promoting inflammation in gastric cancers.

Authors:  Sung-Yup Cho; Yumi Oh; Eui Man Jeong; Sanghui Park; Dakeun Lee; Xiaorui Wang; Qiqi Zeng; Hongyu Qin; Fang Hu; Hui Gong; Xi Liu; Guanjun Zhang; Deukchae Na; Jieun Lee; Jeesoo Chae; Yun-Suhk Suh; Seong-Ho Kong; Hyuk-Joon Lee; Jong-Il Kim; Hansoo Park; Chengsheng Zhang; Han-Kwang Yang; Charles Lee
Journal:  Exp Mol Med       Date:  2020-05-28       Impact factor: 8.718

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.